EFL

Cohort Year: 2019-2020

Tracks: Life Sciences

VISIT WEBSITE

Synthis

Synthis is developing a pipeline of novel targeted immuno-oncology therapies to reverse immune suppression in cancer patients. Instead of directly killing the tumor using a cytotoxic payload, Synthis is employing antibody-drug conjugate technology in a novel way to restore immune-mediated tumor clearance.